These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12744865)

  • 41. Effectiveness and safety of pandemic influenza A (H1N1) 2009 vaccine in healthcare workers at a university hospital in Japan.
    Igari H; Watanabe A; Chiba H; Shoji K; Segawa S; Nakamura Y; Watanabe M; Suzuki K; Sato T
    Jpn J Infect Dis; 2011; 64(3):177-82. PubMed ID: 21617299
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differences in efficiency, satisfaction and adverse events between self-administered intradermal and nurse-administered intramuscular influenza vaccines in hospital workers.
    Coleman BL; McNeil SA; Langley JM; Halperin SA; McGeer AJ
    Vaccine; 2015 Nov; 33(48):6635-40. PubMed ID: 26529074
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2-49years.
    Baxter R; Eaton A; Hansen J; Aukes L; Caspard H; Ambrose CS
    Vaccine; 2017 Mar; 35(9):1254-1258. PubMed ID: 28162825
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children.
    Piedra PA; Yan L; Kotloff K; Zangwill K; Bernstein DI; King J; Treanor J; Munoz F; Wolff M; Cho I; Mendelman PM; Cordova J; Belshe RB
    Pediatrics; 2002 Oct; 110(4):662-72. PubMed ID: 12359778
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults.
    Leeb A; Carcione D; Richmond PC; Jacoby P; Effler PV
    Vaccine; 2011 Oct; 29(45):7920-4. PubMed ID: 21864621
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
    Englund JA; Walter E; Black S; Blatter M; Nyberg J; Ruben FL; Decker MD;
    Pediatr Infect Dis J; 2010 Feb; 29(2):105-10. PubMed ID: 19934787
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old.
    Hambidge SJ; Glanz JM; France EK; McClure D; Xu S; Yamasaki K; Jackson L; Mullooly JP; Zangwill KM; Marcy SM; Black SB; Lewis EM; Shinefield HR; Belongia E; Nordin J; Chen RT; Shay DK; Davis RL; DeStefano F;
    JAMA; 2006 Oct; 296(16):1990-7. PubMed ID: 17062862
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip.
    Delore V; Salamand C; Marsh G; Arnoux S; Pepin S; Saliou P
    Vaccine; 2006 Mar; 24(10):1586-92. PubMed ID: 16271424
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
    Avila Aguero ML; Soriano-Fallas A; Umaña-Sauma MA; Ulloa-Gutierrez R; Arnoux S
    Medicina (B Aires); 2007; 67(4):351-9. PubMed ID: 17891930
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season.
    Kawai AT; Li L; Kulldorff M; Vellozzi C; Weintraub E; Baxter R; Belongia EA; Daley MF; Jacobsen SJ; Naleway A; Nordin JD; Lee GM
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):548-53. PubMed ID: 24497128
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Similar immunogenicity of the A/H1N1 2009 pandemic influenza strain when used as a monovalent or a trivalent vaccine.
    Van der Vliet D; Pepin S; Lambert M; Fauchoux N; Donazzolo Y; Dupuy M; Dakowski C; Denis M
    Hum Vaccin; 2010 Oct; 6(10):823-8. PubMed ID: 20935517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quadrivalent inactivated influenza vaccine (VaxigripTetra™).
    Gresset-Bourgeois V; Leventhal PS; Pepin S; Hollingsworth R; Kazek-Duret MP; De Bruijn I; Samson SI
    Expert Rev Vaccines; 2018 Jan; 17(1):1-11. PubMed ID: 29157068
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recurrent Guillain-Barre syndrome following vaccination.
    Baxter R; Lewis N; Bakshi N; Vellozzi C; Klein NP;
    Clin Infect Dis; 2012 Mar; 54(6):800-4. PubMed ID: 22267712
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maternal influenza vaccine and risks for preterm or small for gestational age birth.
    Nordin JD; Kharbanda EO; Vazquez Benitez G; Lipkind H; Vellozzi C; Destefano F;
    J Pediatr; 2014 May; 164(5):1051-1057.e2. PubMed ID: 24582484
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 μg) in two European countries during influenza season 2016/17 and comparison with 2015/16 season.
    Chabanon AL; Bricout H; Ballandras C; Souverain A; Caroe TD; Butler KM
    Hum Vaccin Immunother; 2018 Feb; 14(2):378-385. PubMed ID: 29148911
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serious adverse events following receipt of trivalent inactivated influenza vaccine in Korea, 2003-2010.
    Choe YJ; Cho H; Kim SN; Bae GR; Lee JK
    Vaccine; 2011 Oct; 29(44):7727-32. PubMed ID: 21827815
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity and safety of a cell culture-derived inactivated trivalent influenza vaccine (NBP607): A randomized, double-blind, multi-center, phase 3 clinical trial.
    Song JY; Cheong HJ; Lee J; Woo HJ; Wie SH; Lee JS; Kim SW; Noh JY; Choi WS; Kim H; Kim KH; Kim WJ
    Vaccine; 2015 Oct; 33(41):5437-5444. PubMed ID: 26314625
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study.
    Heinonen S; Silvennoinen H; Lehtinen P; Vainionpää R; Ziegler T; Heikkinen T
    Lancet Infect Dis; 2011 Jan; 11(1):23-9. PubMed ID: 21106443
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010-May 2016.
    Moro P; Baumblatt J; Lewis P; Cragan J; Tepper N; Cano M
    Drug Saf; 2017 Feb; 40(2):145-152. PubMed ID: 27988883
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adverse Events Following Trivalent Inactivated Influenza Vaccination in Children: Analysis of the Vaccine Adverse Event Reporting System.
    Muhammad R; Haber P; Broder K; Leroy Z; Ball R; Braun MM; Davis RL; McMahon AW
    Pediatr Infect Dis J; 2011 Jan; 30(1):e1-8. PubMed ID: 21042229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.